ESSA Pharma Aktie [WKN DE: A2JKQ4 / ISIN: CA29668H7085]

Kurse + Charts + Realtime		News + Analysen	Fundamental	Unternehmen	zugeh. Wertpapiere	Aktion
Kurs + Chart	Chart (groß)	News + Adhoc	Bilanz/GuV	Termine	Zertifikate	Portfolio
Times + Sales	Chartvergleich	Analysen	Schätzungen	Profil	Optionsscheine	Watchlist
Börsenplätze	Realtime Push	Kursziele	Dividende/GV	Knock-Outs
Historisch	Analysen

Kurse + Charts + Realtime
Kurs + Chart
Times + Sales
Börsenplätze
Historisch

News + Analysen
News + Adhoc
Analysen
Kursziele

Fundamental
Bilanz/GuV
Schätzungen
Dividende/GV
Analysen

Unternehmen
Termine
Profil

zugeh. Wertpapiere
Zertifikate
Optionsscheine
Knock-Outs

Nachrichten zu ESSA Pharma Inc Registered Shs

01.11.24		Cancer-Focused ESSA Pharma Ends Prostate Cancer Trial Due to Insufficient Efficacy From Combination Therapy (Benzinga)
01.11.24		ESSA Stops Phase 2 Study Of Masofaniten Combo In Metastatic Castration-Resistant Prostate Cancer (RTTNews)
13.02.24		ESSA Pharma: Q1 Earnings Insights (Benzinga)
26.01.24		What's Going On With Prostate Cancer Focused ESSA Pharma Stock Today? (Benzinga)
16.01.24		Applied Digital, ESSA Pharma And Other Big Stocks Moving Higher In Tuesday's Pre-Market Session (Benzinga)
12.12.23		Recap: ESSA Pharma Q4 Earnings (Benzinga)
12.12.23		ESSA Pharma Provides Corporate Update and Reports Financial Results for Fiscal Fourth Quarter and Year Ended September 30, 2023 (PR Newswire)
21.11.23		ESSA Pharma to Present at the Piper Sandler 35th Annual Healthcare Conference (PR Newswire)
08.11.23		ESSA Pharma to Present at the Jefferies London Healthcare Conference (PR Newswire)
06.11.23		ESSA Pharma Enters into At-The-Market Equity Offering Sales Agreement (PR Newswire)
26.10.23		ESSA Pharma Presents Updated Phase 1 Masofaniten (EPI-7386) Clinical Data at the 30th Annual Prostate Cancer Foundation Scientific Retreat (PR Newswire)
21.10.23		ESSA Pharma Presents Updated Phase 1 Masofaniten (EPI-7386) Clinical Data at the European Society of Medical Oncology 2023 Congress (PR Newswire)
18.09.23		ESSA Pharma Announces Initiation of Phase 2 Study Evaluating Masofaniten (EPI-7386) in Combination with Enzalutamide in Patients with Metastatic Castration-Resistant Prostate Cancer (PR Newswire)
31.08.23		ESSA Pharma Insiders Establish Automatic Securities Disposition Plans (PR Newswire)
08.08.23		ESSA Pharma Provides Corporate Update and Reports Financial Results for Fiscal Third Quarter Ended June 30, 2023 (PR Newswire)
06.06.23		ESSA Pharma Appoints Lauren Merendino to its Board of Directors (PR Newswire)
01.06.23		ESSA Pharma to Present at 2023 Jefferies Healthcare Conference (PR Newswire)
11.05.23		ESSA Pharma to Present at JMP Securities Life Sciences Conference (PR Newswire)
09.05.23		ESSA Pharma Provides Corporate Update and Reports Financial Results for Fiscal Second Quarter Ended March 31, 2023 (PR Newswire)
18.04.23		ESSA Pharma to Present at the 2023 Bloom Burton & Co. Healthcare Investor Conference (PR Newswire)
12.04.23		ESSA Pharma Announces Clinical Trial Support Agreement with Janssen to Evaluate EPI-7386 Combinations in Patients with Prostate Cancer (PR Newswire)
08.03.23		ESSA Pharma to Present at the Oppenheimer 33rd Annual Healthcare Conference (PR Newswire)
13.02.23		ESSA Pharma Announces Presentations at the American Society of Clinical Oncology Genitourinary Cancers Symposium (ASCO GU) (PR Newswire)
07.02.23		ESSA Pharma Provides Corporate Update and Reports Financial Results for Fiscal First Quarter Ended December 31, 2022 (PR Newswire)
02.02.23		ESSA Pharma to Participate in the Guggenheim Healthcare Talks 5th Annual Oncology Conference (PR Newswire)
13.12.22		ESSA Pharma Provides Corporate Update and Reports Financial Results for Fiscal Fourth Quarter and Year Ended September 30, 2022 (PR Newswire)
10.11.22		ESSA Pharma to Participate in Two Upcoming Investor Conferences (PR Newswire)
31.10.22		ESSA Provides an Update on its Clinical Collaboration with Janssen (PR Newswire)
26.10.22		ESSA Pharma Presents Preclinical Data for its First Generation Androgen Receptor N-Terminal Domain Degrader at the 34th EORTC-NCI-AACR Symposium (PR Newswire)
26.10.22		Updated Results from the Phase 1/2 Study of ESSA's Lead Candidate EPI-7386 in Combination with Enzalutamide Highlighted at the 29th Annual Prostate Cancer Foundation Scientific Retreat (PR Newswire)
13.09.22		ESSA Pharma Appoints Philip Kantoff to its Board of Directors (PR Newswire)
04.08.22		ESSA Pharma Provides Corporate Update and Reports Financial Results for Fiscal Third Quarter Ended June 30, 2022 (PR Newswire)
27.06.22		ESSA Pharma Presents Clinical Update on EPI-7386 Monotherapy and Combination Therapy Clinical Development (PR Newswire)
02.06.22		ESSA Pharma to Present at 2022 Jefferies Healthcare Conference (PR Newswire)
10.05.22		ESSA Pharma Provides Corporate Update and Reports Financial Results for Fiscal Second Quarter Ended March 31, 2022 (PR Newswire)
26.04.22		ESSA Pharma to Present at the 2022 Bloom Burton & Co. Healthcare Investor Conference (PR Newswire)
08.04.22		ESSA Pharma Announces the Presentation of Preclinical Data for its First Generation of Androgen Receptor N-Terminal Domain Degraders (PR Newswire)
10.03.22		ESSA Pharma to Present at Oppenheimer Annual Healthcare Conference (PR Newswire)
10.03.22		ESSA PHARMA INC. REPORTS RESULTS OF ANNUAL GENERAL MEETING OF SHAREHOLDERS (PR Newswire)
08.03.22		ESSA Pharma to Present Preclinical Data for its First Generation of Androgen Receptor N-Terminal Domain Degraders at the 2022 American Association for Cancer Research (AACR) Annual Meeting (PR Newswire)
03.02.22		ESSA Pharma Provides Corporate Update and Reports Financial Results for Fiscal First Quarter Ended December 31, 2021 (PR Newswire)
19.01.22		ESSA Pharma Announces First Patient Dosed in a Phase 1/2 Clinical Trial of EPI-7386 in Combination with Enzalutamide in Patients with Metastatic Castration-Resistant Prostate Cancer (PR Newswire)
18.11.21		ESSA Pharma Provides Corporate Update and Reports Financial Results for Fiscal Fourth Quarter and Year Ended September 30, 2021 (PR Newswire)
08.11.21		ESSA Pharma to Participate in Three Upcoming Investor Conferences (PR Newswire)
28.10.21		ESSA Pharma Presents at 28th Annual Prostate Cancer Foundation Scientific Retreat (PR Newswire)
07.10.21		ESSA Pharma Announces the Presentation of Preclinical Data Characterizing the Mechanism of Action of EPI-7386 (PR Newswire)
07.10.21		Caris Life Sciences and ESSA Pharma Announce Liquid Biopsy Profiling Collaboration (PR Newswire)
31.08.21		ESSA Pharma to Present at Upcoming September Investor Conferences (PR Newswire)
16.08.21		ESSA Pharma Provides Corporate Update and Reports Financial Results for Fiscal Third Quarter Ended June 30, 2021 (PR Newswire)
16.08.21		ESSA Pharma Provides Corporate Update and Reports Financial Results for Fiscal Third Quarter Ended June 30, 2021 (PR Newswire)

1 | Weiter

Newssuche

Meistgelesene Nachrichten

Pierer Mobility-Aktie schwach: Gehälter für Angestellte von insolventer KTM noch vor Weihnachten

Bundesheer wirbt nach KTM-Insolvenz um Mitarbeiter - Pierer Mobility-Aktie im Plus

Ethereum Kurs Prognose: ETH massiv unterbewertet! Fällt jetzt das ATH?

Zalando-Aktie im Plus, ABOUT YOU-Aktie mit Kurssprung: Zalando unterbreitet Übernahmeangebot für ABOUT YOU

NASDAQ 100: Palantir und MicroStrategy vor der Aufnahme - Was Anleger wissen sollten

TUI-Aktie im Plus: Gewinne dank Urlauber-Ansturm

finanzen.net Apps

ETF-Sparplan

Oskar ist der einfache und intelligente ETF-Sparplan. Er übernimmt die ETF-Auswahl, ist steuersmart, transparent und kostengünstig.

JETZT MEHR ERFAHREN

Aktien ATX DAX EuroStoxx 50 Dow Jones NASDAQ 100 Nikkei 225 S&P 500

Kontakt - Impressum - Werbung

Sitemap - Datenschutz - Disclaimer - AGB - Privatsphäre-Einstellungen

Für die aufgeführten Inhalte kann keine Gewährleistung für die Vollständigkeit, Richtigkeit und Genauigkeit übernommen werden.
Kursinformationen von SIX Financial Information Deutschland GmbH. Verzögerung 15 Min. (Nasdaq, NYSE: 20 Min.).
© 1999-2024 finanzen.net GmbH

*Werbehinweise: Die Billigung des Basisprospekts durch die Bundesanstalt für Finanzdienstleistungsaufsicht ist nicht als ihre Befürwortung der angebotenen Wertpapiere zu verstehen. Wir empfehlen Interessenten und potenziellen Anlegern den Basisprospekt und die Endgültigen Bedingungen zu lesen, bevor sie eine Anlageentscheidung treffen, um sich möglichst umfassend zu informieren, insbesondere über die potenziellen Risiken und Chancen des Wertpapiers. Sie sind im Begriff, ein Produkt zu erwerben, das nicht einfach ist und schwer zu verstehen sein kann.

⁵Hinweis zu Plus500: 82% der Kleinanlegerkonten verlieren Geld beim CFD-Handel mit diesem Anbieter. Sie sollten überlegen, ob Sie es sich leisten können, das hohe Risiko einzugehen, Ihr Geld zu verlieren. Plus500UK Ltd ist zugelassen und reguliert durch Financial Conduct Authority (FRN 509909). Plus500CY Ltd authorized & regulated by CySEC (#250/14).

Währungsrechner News Devisen Dollarkurs Aktienkurse Bitcoin Rohstoffe Fonds

Portfolioname: Watchlistname:
Portfolio:
Name:
Typ:
ISIN:
Börse:
Anzahl:
Aktueller Kurs:
Kurszeit:
Kaufpreis:
Kaufdatum:	13.12.2024 17:51
Kaufwert:	EUR
	Hinzufügen Speichern